Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20218734 | 1.00 | MEN1 (0.32) | MEN1KMT2AADAM17PTGIRMAPK1 | |
| SCHEMBL20536596 | 1.00 | MEN1 (0.32) | MEN1KMT2AADAM17PTGIRMAPK1 | |
| SCHEMBL20994229 | 0.92 | PTGIR (0.39) | MEN1KMT2APTGIRMAPK1TP53 | |
| SCHEMBL20994733 | 0.90 | — | — | |
| SCHEMBL20536873 | 0.90 | — | — | |
| SCHEMBL20536871 | 0.90 | — | — | |
| SCHEMBL20536955 | 0.88 | — | — | |
| SCHEMBL20536953 | 0.88 | — | — | |
| SCHEMBL20218741 | 0.84 | MEN1 (0.31) | MEN1KMT2APTGIR | |
| SCHEMBL14715871 | 0.83 | CYP4F2 (0.32) | MEN1KMT2AADAM17MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483168-B1 | PROCESSES FOR PREPARING CYCLOPENTA[B]NAPHTHALENOL DERIVATIVES AND INTERMEDIATES THEREOF | CHIROGATE INT INC (TW) | 2020-06-03 | — | — | EP | disclosed |
| EP-3483168-A1 | PROCESSES FOR PREPARING CYCLOPENTA[B]NAPHTHALENOL DERIVATIVES AND INTERMEDIATES THEREOF | Chirogate International Inc. (TW) | 2019-05-15 | — | — | EP | disclosed |
| US-10106499-B1 | Processes for preparing cyclopenta[b]naphthalenol derivatives and intermediates thereof | CHIROGATE INTERNATIONAL INC. (TW) | 2018-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106499-B1 | Processes for preparing cyclopenta[b]naphthalenol derivatives and intermediates thereof | PTGES, PTGIS, PTGS1 | MEN1 1496/4885KMT2A 4755/4885ADAM17 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.